Immunomedics Reports New Blood Test for Detecting Early Stage Pancreatic Cancer Correlates With Response to Clivatuzumab Tetraxetan Treatment - MarketWatch

Immunomedics Reports New Blood Test for Detecting Early Stage Pancreatic Cancer Correlates With Response to Clivatuzumab Tetraxetan Treatment - MarketWatch

Immunomedics, Inc. /quotes/comstock/15*!immu/quotes/nls/immu (IMMU 3.72, 0.00, 0.00%) , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.
Posted using ShareThis